A new oral treatment for chronic pain in irritable bowel syndrome
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome
This study is testing a new oral treatment made from a special probiotic yeast that aims to help people with irritable bowel syndrome (IBS) by reducing chronic pain and improving their overall gut health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fzata, INC. NIH-funded |
| Lab location | 1 site (Halethorpe, United States) |
| Project ID | NIH-10976389 on NIH RePORTER |
What this research studies
This research investigates a novel oral biotherapeutic designed to alleviate chronic visceral pain associated with irritable bowel syndrome (IBS). The approach focuses on targeting tumor necrosis factor-alpha (TNF-α), a key inflammatory mediator linked to pain in IBS patients. By using an engineered probiotic yeast that produces a neutralizing antibody against TNF-α, the study aims to reduce pain and improve the quality of life for those suffering from this condition. Patients will be monitored for pain relief and overall gastrointestinal health during the treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with irritable bowel syndrome who experience chronic visceral pain.
Not a fit: Patients with IBS who do not experience chronic visceral pain or those with other underlying gastrointestinal disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from chronic pain due to irritable bowel syndrome.
How similar studies have performed: Previous research has shown promise in targeting TNF-α for pain management, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Halethorpe, United States
- Fzata, INC. — Halethorpe, United States (Active)
Researchers
- Principal investigator: Yang, Zhiyong — Fzata, INC.
- Study coordinator: Yang, Zhiyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.